FDA clarifies that no drugs are approved to treat COVID-19 after Trump names 2 contenders
President Trump held up two drugs as possible treatments for COVID-19, the disease caused by the new coronavirus, in a conference call with governors on Thursday. He said chloroquine, an older drug used to treat malaria, lupus, and rheumatoid arthritis, was "very powerful" and has shown "very, very encouraging early results," adding that the Food and Drug Administration has approved the drug for use against the coronavirus.
The FDA said in a subsequent statement that "there are no FDA-approved therapeutics or drugs to treat, cure, or prevent COVID-19." Doctors can prescribe chloroquine "off-label," for unapproved uses, to treat COVID-19 patients.
Chloroquine, which can be lethal if taken by children or in large doses, will be tested in a "large, pragmatic clinical trial" with coronavirus patients, FDA Commissioner Stephen Hahn told reporters after Trump's briefing. German pharmaceutical giant Beyer said Thursday it is donating 3 million tablets of its chloroquine phosphate drug, Resochin, to the U.S. government for COVID-19 treatment research. Resochin is not currently approved for use in the U.S. Rising Pharmaceuticals, the only U.S. manufacturer of chloroquine, nearly doubled the drug's price on Jan. 23 — then restored the original price after an outcry, calling the price hike "coincidental," the Financial Times reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Dr. Ross McKinney Jr., chief scientific officer for the Association of American Medical Colleges, told reporters Thursday that while chloroquine may look promising in test tubes, he's "skeptical it will be effective" in COVID-19 patients. Infectious disease experts are more optimistic about the other treatment Trump mentioned, the experimental antiviral drug remdesivir from Gilead Sciences. Remdesivir is being tested in at least five experiments.
Researchers are also experimenting with HIV medications, several treatments for rheumatoid arthritis, and the Japanese flu medicine favipiravir, The Associated Press reports. "We're looking at drugs that are already approved for other indications" as stopgap treatments, Hahn said, but "we want to make sure this is done well and right."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Women are getting their own baseball league again
In the Spotlight The league is on track to debut in 2026
By Justin Klawans, The Week US Published
-
Giant TVs are becoming the next big retail commodity
Under the Radar Some manufacturers are introducing TVs over 8 feet long
By Justin Klawans, The Week US Published
-
When will mortgage rates finally start coming down?
The Explainer Much to potential homebuyers' chagrin, mortgage rates are still elevated
By Becca Stanek, The Week US Published
-
Boeing machinists approve contract, end strike
Speed Read The company's largest union approved the new contract offer, ending a seven-week strike
By Peter Weber, The Week US Published
-
US economy still strong in final preelection report
Speed Read It grew at a solid 2.8% annual rate from July through September
By Peter Weber, The Week US Published
-
Boeing machinists reject deal, continue strike
Speed Read The rejection came the same day Boeing reported a $6.2 billion quarterly loss
By Peter Weber, The Week US Published
-
Ports reopen after dockworkers halt strike
Speed Read The 36 ports that closed this week, from Maine to Texas, will start reopening today
By Peter Weber, The Week US Published
-
'Brain drain' fear as record numbers leave New Zealand
Under The Radar Neighbouring Australia is luring young workers with prospect of better jobs
By Chas Newkey-Burden, The Week UK Published
-
Ghost kitchens are pulling a disappearing act
under the radar The delivery-only trend is failing to live up to the hype built up during the pandemic
By Theara Coleman, The Week US Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published